Clinical or radiographic evidence of metastatic disease; metastatic workup is not required, but is recommended for patients with clinical stage III disease; Note: isolated ipsilateral supraclavicular node involvement is permitted Patients with evidence of metastatic disease involvement in viscera or bone Radiographic evidence of intratumor cavitation. Patients with evidence of myelodysplasia Evidence of other immune related disease /conditions. Evidence or high suspicion of metastatic disease at enrollment No evidence of extrahepatic metastatic disease Pathologically confirmed squamous cell carcinoma of the head and neck with evidence of metastatic disease or locally recurrent disease considered incurable by local therapies; patients without pathologic or cytologic evidence of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation Histologic evidence of DDLS at any time prior to randomization AND current evidence of DDLS requiring treatment Pathologically proven, radiologic or clinical evidence of distant metastatic disease (this includes all disease below the clavicles, as well as disease metastatic to the bone, brain, or in the spinal canal) Patient has evidence of metastatic disease Evidence of metastatic disease TREATMENT WITH SJCAR: Evidence of active, uncontrolled neurologic disease Has evidence of metastatic disease at time of diagnosis. Evidence of metastatic disease No evidence of metastatic disease as determined by imaging procedures. Documented evidence of active acromegaly Radiographic evidence of metastatic disease Unequivocal evidence of metastatic disease defined by computerized tomography (CT) (includes resectable metastases) Evidence of metastatic disease. Clinically no evidence of local, regional, or metastatic disease at the time of study entry Cross-sectional imaging evidence of progression of recurrent/metastatic disease Clinically node negative, no evidence of metastatic disease Radiographic evidence of metastatic disease Evidence of metastatic disease that is extensive enough to preclude consideration of subsequent definitive surgery for the primary tumor Clinical evidence of progression of disease > % in the breast or new evidence of nodal metastases Known evidence of active cerebral/meningeal CLL; patients may have a history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration (defined as >= consecutive spinal fluid assessments with no evidence of disease) No evidence of hydronephrosis Evidence of disease by standard morphologic or by minimal residual disease (MRD) criteria Diagnosis of widespread visceral and/or osseous metastatic disease based on clinical and radiographic evidence; (patients may continue on study if surgery shows a non-malignant process) Participants with LL must have radiographic evidence of disease Absence of radiographic evidence of extrathyroidal extension Evidence of ischemic heart disease as determined by study cardiologist Evidence of metastatic disease Known evidence of active cerebral/meningeal disease; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease (defined as >= consecutive spinal fluid assessments with no evidence of disease) at that time of registration Evidence of hemachromatosis. Evidence of metastatic disease No evidence of metastatic disease No clinical or radiological evidence of metastatic disease or local progression Any evidence of metastatic disease M stage based on no evidence of metastatic disease by CT imaging. Evidence of other immune related disease/conditions. Clinical evidence or known history of cardiopulmonary disease Evidence of metastatic disease Patients with clinical evidence of metastatic disease. Evidence of ischemic heart disease as determined by study cardiologist Prior evidence of p/q co-deletion Patients with evidence of extraneural disease Patients with evidence of metastatic disease involvement in viscera or bone Radiographic evidence of metastatic disease Clinical, radiographic or pathologic evidence of multicentric disease No evidence of metastatic disease by clinical and radiological staging Evidence or suspicion of disease metastatic to sites remote from the supratentorial brain Patients must have evidence of metastatic disease (non measurable disease is eligible) Radiological evidence of metastatic disease Patients with evidence of metastatic disease outside of the pelvis Evidence of metastatic disease outside of the abdomen Evidence of metastatic disease outside of the abdomen Current or previous evidence of muscle invasive (muscularis propria) or metastatic disease presented at the screening visit. Examples that increase the risk of metastatic disease are (but not limited to): Patient with documented evidence of metastatic disease Prior or present evidence of distant metastatic disease as assessed by radiographic imaging; No prior or present evidence of metastatic disease; Evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging. Patients must have no evidence of muscle invasive disease Evidence of metastatic disease on cross sectional imaging or bone scan Clinical or radiographic evidence of metastatic disease; metastatic workup is not required\r\n* Note: isolated ipsilateral supraclavicular node involvement is permitted Evidence of extrauterine spread of disease on imaging or during surgical evaluation Definite evidence of metastatic disease There is no evidence of disease relapse at the time of screening, and minimal residual disease (MRD) is acceptable Evidence of metastatic disease No evidence of disease at the time of registration, including no clinical concern for disease recurrence based on each of the following:\r\n* No evidence of disease by history and physical exam\r\n* Cancer antigen (CA) within normal limits\r\n* Computed tomography (CT) abdomen/pelvis demonstrating no radiological evidence of disease performed after completion of chemotherapy =< days before entering study Evidence of metastatic disease Patients must not have evidence of metastatic tumor or other cancer Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least days before first dose of pembrolizumab. No evidence of disease by standard morphology; minimal residual disease or molecular evidence of disease will not exclude Currently have no clinical evidence of disease No evidence of extranodal metastatic disease Patients must not have intra-operative evidence of Tb disease Resectable primary tumor with no evidence of metastatic disease by imaging. Imaging must be performed within days of Day of study. CT or MRI evidence of metastatic disease to the bone Evidence of extrauterine spread of disease on imaging or during surgical evaluation Patients with only locally or regionally confined disease without evidence of metastatic disease No evidence of metastatic disease Evidence or suspicion of disease metastatic to sites remote from supratentorial brain Clinical (e.g. multiple new cranial nerve deficits in the absence of obvious radiographic disease to explain symptoms) or radiographic evidence of leptomeningeal disease Has a prior history or current evidence of intracranial (CNS) metastatic RCC, except for ? lesions treated by CyberKnife or excisional surgery, clinically stable for at least weeks, and without evidence of recurrence on MRI imaging at screening. Evidence of nephrectomy Radiographic evidence of disease Participants with evidence of non-hepatic metastatic disease No evidence of known metastatic disease (M or Mx allowed) Evidence of significant hepatic, hematologic, or immunologic disease. Presence of distant metastatic disease; patients will undergo radiographic evaluation to exclude the possibility of distant metastatic disease; for patients who have undergone pre- or postoperative biopsies that definitively diagnose ICC, the diagnostic studies may be modified at the discretion of the MSKCC principal investigator; clinical or radiographic evidence of metastatic disease to regional lymph nodes will be allowed, provided it is amenable to resection Completely resected hepatic metastases without current evidence of other metastatic disease Radiographic evidence of disease Radiographic evidence measurable of residual or metastatic disease after surgery Evidence of metastatic disease on imaging studies No evidence of disease Clinical evidence of metastatic disease Have no current evidence of disease Survivors must not have evidence of recurrent or metastatic disease Evidence of complete response at three months post-treatment; maintenance therapy is permitted as long as there is no evidence of disease Patients seen in the SCC with a diagnosis of cancer with or without evidence of metastatic disease No known evidence of disease Have no evidence of recurrence or metastatic disease Patients with evidence of muscle-invasion or metastatic disease will be excluded Patients who currently have no evidence of disease Evidence of or treatment for metastatic disease Clinical (e.g. multiple cranial nerve deficits in the absence of obvious radiographic disease to explain symptoms) or radiographic evidence of leptomeningeal disease Evidence of relapsed disease Patients must be without evidence of M Evidence of malignancy within months of study enrollment; this is defined as clear morphologic, radiologic or molecular evidence of disease; mixed chimerism is allowed at the discretion of the clinician No evidence of residual disease on scan No evidence of disease metastatic to bone marrow. Clinical or radiographic evidence of metastatic disease Clinical evidence of metastatic (Tb, any N; any T, N-; M) disease Clinical or radiological evidence of metastatic disease Patients must be without evidence of residual disease as assessed by their treatment team No evidence of disease Patients must have evidence of disease either through elevation of tumor markers or radiologic evidence of disease Participants with known clinical or radiographic evidence of metastatic CNS disease No evidence of peritoneal disease on preoperative imaging Radiographic evidence of metastatic disease No evidence of metastatic disease Has no evidence of disease